MedPath

Lakewood-Amedex Inc.

Lakewood-Amedex Inc. logo
🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

3

Active:0
Completed:1

Trial Phases

2 Phases

Phase 1:1
Phase 2:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Phase 2
2 (66.7%)
Phase 1
1 (33.3%)

Nu-3 Gel for Infected Diabetic Foot Ulcers

Phase 2
Not yet recruiting
Conditions
Diabetic Foot Infection
Interventions
First Posted Date
2023-08-31
Last Posted Date
2025-03-06
Lead Sponsor
Lakewood-Amedex Inc
Target Recruit Count
60
Registration Number
NCT06020235

Nu-3 Topical Gel for Treatment of Diabetic Foot Ulcer

Phase 2
Terminated
Conditions
Chronic Diabetic Foot Ulcers
Interventions
Drug: 5% Bisphosphocin Topical Gel
Drug: Placebo Topical Gel
Drug: 10% Bisphosphocin Topical Gel
First Posted Date
2022-03-11
Last Posted Date
2024-01-30
Lead Sponsor
Lakewood-Amedex Inc
Target Recruit Count
3
Registration Number
NCT05276401
Locations
🇺🇸

NEA Baptist Clinic, Jonesboro, Arkansas, United States

🇺🇸

Limb Preservation Platform, Inc., Fresno, California, United States

🇺🇸

Doctors Research Network, South Miami, Florida, United States

and more 2 locations

Topically Applied Bisphosphocin Nu-3 on Infected Diabetic Ulcers of Subjects With Type I or II Diabetes Mellitus

Phase 1
Completed
Conditions
Diabetic Foot Infections
Interventions
First Posted Date
2016-04-14
Last Posted Date
2019-11-19
Lead Sponsor
Lakewood-Amedex Inc
Target Recruit Count
31
Registration Number
NCT02737722
Locations
🇺🇸

Center for Clinical Research, Inc., San Francisco, California, United States

🇺🇸

Journey Research, Inc., Oldsmar, Florida, United States

🇺🇸

Clinical Research Solutions, Franklin, Tennessee, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.